biotherapy (immunotherapy)
Jump to navigation
Jump to search
Introduction
Use of the immune system directly or indirectly to treat disease, especially cancer. May include administration of biologic agents such as:
- adoptive immunotherapy
- lymphokine-activated killer [LAK] cells
- tumor-infiltrating lymphocytes [TILs])
- hematopoietic growth factors
- interferons
- interferon alfa-2a (Roferon-A)
- interferon alfa-2b (Intron-A)
- pegylated interferon (Pegasys)
- interferon alfa-n3 (Alferon N)
- interferon alfacon-1 (Infergen)
- interferon beta-1a (Avonex)
- interferon beta-1b (Betaseron)
- interferon gamma-1b (Actimmune)
- interleukins
- monoclonal antibodies
- levamisole (Ergamisol)
- fusion proteins
- tumor necrosis factor
- vaccines
or procedures such as
- gene therapy
- donor-derived T cells that simultaneously target different opportunistic viruses
Notes
- dubbed 'breakthrough of the year' in 2013[3]
- investigational
- viral vectors carrying genes for normal prostate tissue infused into mice resulted in regression of subcutaneous prostate tumors without effect on the normal mouse prostate
- there was no activity against melanoma
- viral vectors carrying genes for normal skin had no effect on the subcutaneous prostate tumors[2]
- lymphocytes were extracted from lung metastases in a patient with cholangiocarcinoma
- lymphocytes that showed activity against mutations found only in the tumor were harvested, cloned, & reinfused
- the patient's tumors allegedly began 'melting away'[4]
- donor-derived T cells that simultaneously target 5 different opportunistic viruses reported
- viral vectors carrying genes for normal prostate tissue infused into mice resulted in regression of subcutaneous prostate tumors without effect on the normal mouse prostate
More general terms
More specific terms
Additional terms
References
- ↑ Biological Therapies: Using the Immune System To Treat Cancer http://cis.nci.nih.gov/fact/7_2.htm
- ↑ 2.0 2.1 Kottke T et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med 2011 Jul; 17:854. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21685898
Alvarez-Breckenridge C and Chiocca EA. A viral strategy to ambush tumors. Nat Med 2011 Jul; 17:784 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21738155 - ↑ 3.0 3.1 Couzin-Frankel J Cancer Immunotherapy Science 2013: Vol. 342 no. 6165 pp. 1432-1433 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24357284 <Internet> http://www.sciencemag.org/content/342/6165/1432.full
- ↑ 4.0 4.1 Elia J Treatment Approach Expands Population of Tumor-Infiltrating Lymphocytes. Physician's First Watch, May 12, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
Tran E et al Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. Science 9 May 2014: Vol. 344 no. 6184 pp. 641-645 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24812403 <Internet> http://www.sciencemag.org/content/344/6184/641.abstract - ↑ Komaroff AL Immunotherapy Against Multiple Opportunistic Viruses in Immunocompromised Patients NEJM Journal Watch. July 10, 2014 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
Papadopoulou A at al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014 Jun 25; 6:242ra83 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24964991 <Internet> http://stm.sciencemag.org/content/6/242/242ra83 - ↑ Komaroff AL Immunotherapy to Fight Cancer Begins to Work. NEJM Journal Watch. June 16, 2015 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
Rosenberg SA and Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015 Apr 3; 348:62 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25838374
June CH et al. Adoptive cellular therapy: A race to the finish line. Sci Transl Med 2015 Mar 25; 7:280ps7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25810311
Sharma P and Allison JP. The future of immune checkpoint therapy. Science 2015 Apr 3; 348:56. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25838373
Schumacher TN and Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015 Apr 3; 348:69. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25838375
Mueller KL. Cancer immunology and immunotherapy. Realizing the promise. Science 2015 Apr 3; 348:54. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25838372
Joyce JA and Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015 Apr 3; 348:74 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25838376
Wolchok JD and Chan TA. Cancer: Antitumour immunity gets a boost. Nature 2014 Nov 27; 515:496. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25428495
Brahmer J et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015 May 31 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26028407
Larkin J et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015 May 31; PMID: https://www.ncbi.nlm.nih.gov/pubmed/26027431
Le DT et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015 May 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26028255
Lonial S et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015 Jun 2; PMID: https://www.ncbi.nlm.nih.gov/pubmed/26035255 - ↑ Grady D Harnessing the Immnune System to Fight Cancer. New York Times. July 30, 2016 http://www.nytimes.com/2016/07/31/health/harnessing-the-immune-system-to-fight-cancer.html